These results imply that SPOP cannot be viewed as classically ‘undruggable’, and opens up the avenue that small molecule-targeting cytoplasmic SPOP signaling might be more specific to ccRCC cells, which would be a promising strategy to combat kidney cancer in future therapies. This evidence concerns the gene SPOP and nonpapillary renal cell carcinoma.